NEW YORK (GenomeWeb News) – Linguamatics said today that AstraZeneca has extended its license for the company's I2E text-mining platform in a multi-year deal.
AstraZeneca has been a Linguamatics customer since 2003.
Financial terms of the agreement were not disclosed.
Ian Dix, who heads AstraZeneca's knowledge engineering capability team, said in a statement that the company is using I2E "for knowledge discovery to support better-informed scientific decision-making, impacting discovery performance and competitiveness." In particular, he said that the software is useful for early prediction of candidate drug efficacy and safety.